Get the Stockscreener App
3.64
2.82%
0.10
Pre-market:
3.59
-0.05
-1.37%
Recursion Pharmaceuticals Inc stock is traded at $3.64, with a volume of 16.11M.
It is up +2.82% in the last 24 hours and down -6.67% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.54
Open:
$3.6
24h Volume:
16.11M
Relative Volume:
0.76
Market Cap:
$1.89B
Revenue:
$43.69M
Net Income/Loss:
$-715.54M
P/E Ratio:
-2.011
EPS:
-1.81
Net Cash Flow:
$-450.20M
1W Performance:
-3.45%
1M Performance:
-6.67%
6M Performance:
-19.47%
1Y Performance:
-43.74%
1-Day Range:
$3.53
$3.76
1-Week Range:
$3.44
$3.79
52-Week Range:
$2.98
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.64 | 1.84B | 43.69M | -715.54M | -450.20M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - simplywall.st
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares - TradingView
Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech - DirectorsTalk Interviews
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead (NASDAQ:RXRX) - Seeking Alpha
RXRX: Integrated platform, strong partnerships, and disciplined pipeline drive innovation and growth - TradingView
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure - Markets Mojo
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline - Sahm
Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview - marketscreener.com
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis - Sahm
Recursion Pharmaceuticals Opens with 11.05% Gain Despite Recent Declines - Markets Mojo
Recursion Pharmaceuticals (RXRX) hits clinical milestones as 2025 revenue grows to $74.7M - MSN
Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M - Yahoo Finance
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026 - Meyka
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue - simplywall.st
Recursion Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-02-25 - Seeking Alpha
Recursion Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Recursion Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate - timothysykes.com
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 EPS and Revenue Estimates - MEXC
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic (NASDAQ:RXRX) - Seeking Alpha
BofA cuts Recursion Pharmaceuticals stock price target on launch timing - Investing.com
Recursion (RXRX) Q4 2025 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ) - Seeking Alpha
Recursion’s AI-Enabled Drug Discovery Wins Spotlight at NVIDIA’s Conference - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results - MarketBeat
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - The Globe and Mail
What's Behind The Jump In Recursion Pharmaceuticals Stock? - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Recursion Pharmaceuticals Receives Spotlight with AI-driven Innovations at NVIDIA’s GTC - StocksToTrade
Recursion Q4 2025 slides: AI platform delivers first clinical proof-of-concept - Investing.com UK
Earnings call transcript: Recursion Pharmaceuticals beats Q4 2025 forecasts - Investing.com
This $4 Stock Could Be Your Ticket to Millionaire Status - AOL.com
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c) - TipRanks
Recursion Pharmaceuticals earnings beat by $0.09, revenue topped estimates - Investing.com UK
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion Highlights AI Validation, Extends Cash Runway to 2028 - TipRanks
Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises - marketscreener.com
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - markets.businessinsider.com
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):